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ABSTRACT A critical appraisal and clinical application of Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal 
microbiota transplantation for recurrent Clostridium difficile infection reduces recurrent urinary tract infection frequency. Clinical 
Infectious Diseases. 2017 Oct 30;65(10):1745–1747. doi: 10.1093/cid/cix618. 
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Clinical Context 
A 73-year-old female with multiple chronic medical problems including obesity, type 2 diabetes, and 
cerebrovascular disease with a history of stroke was admitted for foul-smelling, watery diarrhea. She was 
accompanied by her adult daughter who was her primary caregiver and who provided the entirety of the patient’s 
history. The daughter explained that her mother had two previous episodes of C. difficile infection (CDI) and that 
she recognized the stool consistency and smell immediately the previous night, which prompted her to bring her 
mother to the hospital. The patient was non-ambulatory and minimally responsive for the duration of her 
admission, though the daughter admitted this was not too far from baseline. She also had a gastrostomy tube and 
urinary catheter in place due to her chronic state. 
At admission, the patient was afebrile but had a white blood cell count over 17,000. The patient’s stool tested 
positive for C. difficile. The daughter reported that this was her mother’s third admission CDI, and explained that 
doctors at her previous admission proposed it was likely secondary to extended antibiotic treatment for recurrent 
urinary tract infections in the setting of regular use of a urinary catheter. After discussing treatment options with 
the patient’s daughter, it was agreed that a fecal microbiota transplant (FMT) would be the optimal treatment plan 
given multiple recurrences and the patient’s other chronic medical problems. The patient received the FMT 
through her gastrostomy tube after bowel cleanout, and the daughter reported normalization of her bowel 
movements on day two post-transplant. The patient was discharged with her daughter five days after the 
transplant when her white blood cell count normalized. The daughter was instructed to have the patient follow up 
her primary care provider within one week. 
Clinical Question 
Does fecal microbiota transplant for C. difficile infection provide secondary benefit by reducing the incidence of urinary tract 
infections in at-risk patients? 
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Research Article 
Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal microbiota transplantation for recurrent clostridium difficile 
infection reduces recurrent urinary tract infection frequency. Clinical Infectious Diseases. 2017 Oct 30;65(10):1745–1747. doi: 
10.1093/cid/cix618 
Related Literature 
Literature review began with UpToDate articles addressing fecal microbiota transplantation and recurrent urinary tract infection. 
This was followed by PubMed searches combining the keywords “fecal microbiota transplant” or “fecal transplant” with “multi-drug 
resistant organism.” Additional searches were also conducted combining “fecal microbiota transplant” or “fecal transplant” with 
“urinary tract infection.” These searches yielded only eleven total articles of which five were clinical studies. These searches were 
expanded by exploring the “similar articles” section of the PubMed pages of the articles found for more related material. Google 
searches with the same key worlds also yielded a clinical trial registered with the NIH examining the efficacy of FMT specifically for 
the treatment of recurrent urinary tract infections (UTI), though this study currently has no data yet to report.  
Multiple case reports noting clearance of different multi-drug resistant organisms from the gastrointestinal tract following FMT have 
prompted multiple clinical studies exploring the utility of the procedure for eradication of such bacteria in patients suffering from 
recurrent infections.1-2 A multicenter prospective pilot study performed by Davido et al measured the ability of FMT to successfully 
decolonize Carbapenem-resistant Enterobacteriaceae (CRE) or vancomycin-resistant enterococci (VRE) from a small group of 8 
patients.3 The study found clinical success eradicating CRE in 2 and VRE in 3 out of the 8 patients enrolled at one and three-month 
time points.3 Dubberke et al performed a similar study examining the clearance of VRE in a group of patients receiving FMT for 
recurrent CDI.4 Out of 11 patients who tested positive for VRE, 73% (n=8) became negative following FMT over the course of six-
month follow up.1 A single-center study performed by Millan et al utilized microarray analysis of gut microbiota to demonstrate a 
statistically significant reduction in expression of 354 known antibiotic-resistance genes in bacteria obtained from stool samples of 
patients following FMT for recurrent CDI.5 
The study examined here by Tariq et al was chosen specifically because it was the only clinical study found to examine a legitimate 
clinical outcome (the incidence UTI) rather than just the presence of bacteria capable of causing such infections. The study identified 
patients with a history of three of more UTIs in the past year from a pool of patients with three or more episodes of CDI over the 
same time period. The experimental group was treated with FMT and were monitored for occurrence of UTI over a period of one 
year post-transplant.6 Controls were obtained from the same group patients, but were monitored for occurrence of UTI over the 
course of one year following conventional antibiotic treatment for their third episode of CDI.6 Bacterial speciation and 
susceptibilities were also collected in urine samples to evaluate changes in antibiotic resistance in the before and after time periods. 
Of all the studies explored, Tariq et al was the most recently published in July of 2017. It has also been cited eight times since its very 
recent publication indicating a high level of clinical relevance. 
Critical Appraisal 
This was an un-blinded, controlled, pilot study evaluating the occurrence of UTI, defined by urinary symptoms and positive urine 
culture with >105 colony forming units per mL, in patients receiving FMT for recurrent CDI. Inclusion criteria were patients with at 
least three or more UTIs as well as three or more episodes of CDI confirmed with stool polymerase chain reaction over the course of 
the preceding year. Patients were identified retrospectively at hospital admission for a third episode of CDI and were assigned to 
receive either standard antibiotic therapy or FMT. Sixteen total patients were enrolled in the study with eight each being assigned to 
the FMT or control groups. All patients were then monitored over the following year for recurrence of UTI and CDI. Urine cultures 
and susceptibilities during occurrences of UTI were also compared in the one-year before and after time periods to evaluate for 
prevalence of antibiotic resistance.  
The primary outcome of this study was the occurrence of UTI before and after treatment. The authors observed a significant 
decrease in the frequency of UTI in the FMT group from an average of 4 episodes in the year before, down to 1 episode in the year 
after (p = 0.01 with Wilcoxon rank test). This is in contrast to the control group, which showed no change in the average incidence of 
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UTI at 4 episodes in both before and after time periods. Patients receiving FMT also showed complete resolution of CDI with no 
recurrences in the year after. This was despite a small subset receiving trimethoprim-sulfamethoxazole, nitrofurantoin, or 
gentamicin for UTI episodes. Patients in the control group received either oral vancomycin alone or oral vancomycin and intravenous 
metronidazole rather than FMT for their third episode of CDI. Two patients in the control group (25%) had one subsequent episode 
of CDI in the year after, both of which were managed with oral vancomycin taper. 
A secondary outcome of the study was changes in antibiotic resistance in organisms causing UTI. This was completed by comparing 
antibiotic susceptibilities of E. coli and Klebsiella, the two most commonly cultured organisms found in urine cultures during 
episodes of UTI in enrolled patients. 35 urine samples were evaluated in the year before and 11 in the year after for patients 
receiving FMT versus 13 urine samples in the year before and 9 in the year after for control. Susceptibilities showed a decrease of 
ciprofloxacin-resistant and trimethoprim-sulfamethoxazole-resistant E. coli from 20% in the year before down to 0% in the year after 
in the FMT group. Likewise, nitrofurantoin-resistant Klebsiella moved from 22% before down to 0% after in the FMT group. There 
were no changes in antimicrobial resistance in the before and after time periods for controls. It should be noted that no statistical 
significance was noted for any of the susceptibility data described above. 
The greatest strength of this study is the novelty of the clinical application, considering the paucity of data assessing possible 
secondary benefits of FMT outside of treatment for CDI. This is evidenced by the extremely small number of clinical studies found 
during initial searches on PubMed. In addition, as has been noted, this was the only related study found that examined a clinical 
outcome, in this case occurrence of UTI, rather than variables of more questionable clinical significance such as bacterial 
colonization. Another strength is the relatively objective definition of UTI, which was the primary outcome. This was particularly 
important in this study due to the obvious discrepancies between standard antibiotic treatment and FMT to both patients and 
providers, which would have made blinding impractical and near impossible. 
The greatest weakness of this study was sample size, which limited both the effect size as well as the statistical significance of all 
outcomes. The only outcome to have noted statistical significance was occurrence of UTI in patients before and after FMT. All other 
outcomes, while noting trends, could not establish statistical significance. The small sample size also likely limited the authors’ ability 
to carry out more in-depth statistical analyses between groups rather than just within them, which is another weakness. No direct 
analysis comparing outcomes between FMT and control was carried out. It should be noted that no mechanism of randomization 
was noted within the article. Additionally, the only patient population characteristics to be reported were gender (75% female in 
both groups) and age (78.5 years in FMT versus 85.5 years in control). No other health characteristics were evaluated. The lack of 
extra population statistics is again likely due to the small sample size, which might have shown skewed discrepancies between the 
two groups due to the low numbers.  
A weakness of significant importance is the incomplete standardization of donor stool samples used for FMT. A clear set of 
guidelines for selecting healthy donors was well described by the same group, Tariq et al, in a previous publication and used in this 
study.6-7 However, the guidelines primarily rely on other medical conditions in the donor including obesity, depression, pregnancy, 
and antibiotic exposure among others.7 Not included in analysis of donors was evaluation of specific bacteria present in stool with 
exception for a few possibly virulent organisms such as C. difficile and VRE.7 Subtle differences in donor microbiota could very well 
contribute to differences seen not only in recurrence of UTI and CDI but also in the carriage of different antibiotic resistant 
organisms. This issue was avoided in the study by Dubberke et al by using a standardized fecal microbiota “drug” for FMT called 
RBX2660 in all study subjects. Tariq et al, themselves, acknowledge the general lack of standardization in obtaining donor samples 
for such studies nationally and it is a factor that should be carefully considered in all similar studies moving forward.  
The work conducted by Tariq et al qualifies as a level 2 study following by the Strength of Recommendation Taxonomy (SORT) 
guidelines. The study was the first to explore the very novel ability of FMT in reducing recurrence of UTI. However, weaknesses 
including sample size, statistical power, and lack of stool donor standardization limited its ability to completely describe the clinical 
utility FMT for such applications. Work in the future should focus on maximizing sample size and finding ways to better standardize 
FMTs between patients. 
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Clinical Application 
While limited by sample size (N=16) in addition to a handful of other factors, Tariq et al do demonstrate possible 
utility for FMT in reducing the incidence of recurrent UTIs in patients being treated for CDI. Our patient did meet 
study criteria given the incidence of both CDI and UTI in her recent medical history. Even if she had not met 
criteria, however, she may still have found similar benefit from FMT given her chronic state in addition to her 
elevated risk for UTI with the use of regular urinary catheterization.  
After discussing treatment options with the patient’s daughter, she agreed that FMT would be the best course of 
action. The daughter in fact pushed for FMT as her end goal had always been optimal comfort for her mother, who 
may have benefited twofold with the reduction of both CDI and UTI should the conclusions of Tariq et al hold true. 
Primary learning points: 
1. Repetitive or prolonged use of systemic antibiotics increases risk of developing both CDI and multidrug 
resistant organism carriage, which can predispose to other recurrent infections. 
2. FMT is an effective treatment for recurrent CDI and may have broader clinical application in the prevention of 
recurrent UTI. 
3. More work is needed in evaluating the utility of FMT for the treatment of recurrent UTI both independently 
and in the setting of CDI. 
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